RTP Mobile Logo
Oncology Nursing Update Dermatologic Oncology Edition, Issue 1, 2013
Released December 2013

Featuring interviews with Ms Krista M Rubin and Dr Keith T Flaherty. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Taken together, melanoma and nonmelanoma skin cancers likely represent the most prevalent form of human cancer. Fortunately, the vast majority of skin cancers present as minimally invasive basal cell carcinoma and squamous cell cancer and, as such, are highly curable with local treatment alone. However, in rare instances these characteristically indolent lesions progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, cancerous melanoma is the most aggressive form of skin cancer with a predilection toward distant metastases, even when identified in the early stages of the disease. Thus melanoma and nonmelanoma skin cancer are distinct entities, each posing unique challenges to the oncology nursing community. To provide oncology nurses with therapeutic strategies to address the disparate needs of these patients, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses with expertise in the field. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with melanoma and nonmelanoma skin cancers.

    LEARNING OBJECTIVES

    • Counsel patients considering adjuvant therapy after surgical removal of primary melanoma regarding the risks and potential benefits of high-dose versus pegylated interferon therapy.
    • Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of metastatic melanoma, including chemotherapeutic agents, standard and novel immunotherapeutic strategies and targeted biologic agents.
    • Counsel patients regarding the risk of BRAF inhibitor-associated secondary nonmelanoma skin cancers, and assist patients in managing these and other side effects associated with this targeted approach.
    • Develop a plan to identify and manage the side effects and toxicities associated with immunotherapeutic regimens, including high-dose interleukin-2 and ipilimumab, to support patient quality of life.
    • Discuss the risks and benefits of hedgehog inhibitor therapy in patients with locally advanced or metastatic basal cell carcinoma.

    ACCREDITATION STATEMENT
    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CNE ACTIVITY
    This is an audio CNE program. This website contains learning objectives, faculty disclosures, and links to relevant abstracts and full-text articles.

    To receive credit, participants should read the learning objectives and faculty disclosures and listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Ms RubinAdvisory Committee: Genentech BioOncology, Merck. Dr FlahertyAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi; Consulting Agreements: Genentech BioOncology, GlaxoSmithKline, Momenta Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd, Roche Laboratories Inc; Contracted Research: Novartis Pharmaceuticals Corporation, Sanofi.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology, Merck and Prometheus Laboratories Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    December 2013
    Expiration date: December 2014

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to audio:
Oncology Nursing Update Dermatologic Oncology Edition, Issue 1, 2013
Released December 2013

Featuring interviews with Ms Krista M Rubin and Dr Keith T Flaherty. (Audio Content)

Read print: